Design Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying

内部人士正在买入Design Therapeutics和其他2只低于5美元的股票

Benzinga · 03/26 07:37

The Dow Jones index closed lower by over 150 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

FTC Solar

The Trade: FTC Solar, Inc. (NASDAQ:FTCI) Director Ahmad R Chatila acquired a total of 92,600 shares an average price of $0.55. To acquire these shares, it cost around $50,930.
What's Happening: On March 13, FTC Solar posted upbeat quarterly sales.
What FTC Solar Does: FTC Solar Inc is a provider of solar tracker systems, supported by proprietary software and value-added engineering services.

Ocuphire Pharma

The Trade: Ocuphire Pharma, Inc. (NASDAQ:OCUP) CFO Nirav S. Jhaveri acquired a total of 10,000 shares at at an average price of $2.10. To acquire these shares, it cost around $21,000. The company's COO Joseph K Schachle also bought 2,000 shares.
What's Happening: On March 8, Ocuphire Pharma posted fourth-quarter sales of $1.700 million.
What Ocuphire Pharma Does: Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders.

Design Therapeutics

The Trade: Design Therapeutics, Inc. (NASDAQ:DSGN) Director John P. Schmid acquired a total of 26,965 shares at an average price of $3.70. The insider spent around $99,738 to buy those shares. The company'd Director Heather A. Berger also bought 1,300 shares.
What's Happening: On March 19, Design Therapeutics posted a narrower-than-expected quarterly loss.
What Design Therapeutics Does: Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations.

Don't forget to check out our premarket coverage here

The Dow Jones index closed lower by over 150 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

道琼斯指数周一收盘下跌超过150点。当内部人士购买或出售股票时，这表明他们对公司前景的信心或担忧。对细价股感兴趣的投资者和交易者可以将此视为他们整体投资或交易决策的一个因素。

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

以下是近期一些值得注意的细价股内幕交易。欲了解更多，请查看 本辛加的内幕交易 平台。

FTC Solar

FTC Solar

The Trade: FTC Solar, Inc. (NASDAQ:FTCI) Director Ahmad R Chatila acquired a total of 92,600 shares an average price of $0.55. To acquire these shares, it cost around $50,930.
What's Happening: On March 13, FTC Solar posted upbeat quarterly sales.
What FTC Solar Does: FTC Solar Inc is a provider of solar tracker systems, supported by proprietary software and value-added engineering services.

交易：联邦贸易委员会太阳能公司（纳斯达克股票代码：FTCI）董事艾哈迈德·查蒂拉 共收购了92,600股股票 平均价格为0.55美元。收购这些股票的成本约为50,930美元。
发生了什么：3月13日，联邦贸易委员会太阳能公布了乐观的季度销售额。
联邦贸易委员会太阳能公司的作用：FTC Solar Inc是太阳能跟踪系统的提供商，由专有软件和增值工程服务提供支持。

Ocuphire Pharma

Ocuphire Pharma

The Trade: Ocuphire Pharma, Inc. (NASDAQ:OCUP) CFO Nirav S. Jhaveri acquired a total of 10,000 shares at at an average price of $2.10. To acquire these shares, it cost around $21,000. The company's COO Joseph K Schachle also bought 2,000 shares.
What's Happening: On March 8, Ocuphire Pharma posted fourth-quarter sales of $1.700 million.
What Ocuphire Pharma Does: Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders.

交易：Ocuphire Pharma, Inc.（纳斯达克股票代码：OCUP）首席财务官尼拉夫·贾维里 共收购了 10,000 股股票 平均价格为2.10美元。收购这些股票的成本约为21,000美元。该公司的首席运营官约瑟夫·沙赫尔也购买了2,000股股票。
发生了什么：3月8日，Ocuphire Pharma公布了第四季度销售额为17亿美元。
Ocuphire Pharma做什么：Ocuphire Pharma Inc是一家临床阶段的眼科生物制药公司，专注于开发和商业化治疗屈光和视网膜眼病的疗法。

Design Therapeutics

设计疗法

The Trade: Design Therapeutics, Inc. (NASDAQ:DSGN) Director John P. Schmid acquired a total of 26,965 shares at an average price of $3.70. The insider spent around $99,738 to buy those shares. The company'd Director Heather A. Berger also bought 1,300 shares.
What's Happening: On March 19, Design Therapeutics posted a narrower-than-expected quarterly loss.
What Design Therapeutics Does: Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations.

贸易：Design Therapeutics, Inc.（纳斯达克股票代码：DSGN）董事约翰·施密德 共收购26,965股股票 平均价格为3.70美元。知情人士花费了约99,738美元购买了这些股票。该公司的董事希瑟·伯杰还购买了1300股股票。
发生了什么：3月19日，Design Therapeutics公布的季度亏损低于预期。
Design Therapeutics做什么：Design Therapeutics Inc是一家临床阶段的生物制药公司，从事GenetaCTM分子的研究和开发，这些分子是一种新型的小分子基因靶向嵌合体候选疗法，旨在通过解决遗传性核苷酸重复扩张突变引起的疾病的根本原因来改善疾病。

Don't forget to check out our premarket coverage here

别忘了在这里查看我们的上市前报道

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息